Relmada Therapeutics, Inc.
RLMDRelmada Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system (CNS) disorders and oncology.
Earnings
Next report
Aug 6, 2026 (In 3 weeks)Financials
Q1 2026Valuation & ratios
Competitors
By market cap
Profile
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for central nervous system (CNS) disorders and oncology. The company leverages its drug development expertise to acquire and advance candidates that address high unmet medical needs, particularly in rare diseases and aggressive cancers. Its core value proposition lies in utilizing innovative delivery technologies to improve the efficacy, safety, and administration of established therapeutic agents.
Relmada is a clinical-stage developer transitioning its pipeline toward late-stage trials for niche indications like NMIBC and Prader-Willi syndrome. The company currently has no approved products and competes against large pharmaceutical firms with significantly greater resources.
Questions, answered.
- What is Relmada Therapeutics, Inc.'s market cap?
- Relmada Therapeutics, Inc. (RLMD) has a market capitalization of $683.5M and trades on NASDAQ.
- Who are Relmada Therapeutics, Inc.'s competitors?
- Relmada Therapeutics, Inc.'s key competitors include Johnson & Johnson, Merck & Co., Theriva Biologics, Inc., and others. These companies compete in similar markets and product categories.
- Who does Relmada Therapeutics, Inc. partner with?
- Relmada Therapeutics, Inc.'s notable partners include Trigone Pharma Ltd., Asarina Pharma AB, Arbormentis LLC.
- Where is Relmada Therapeutics, Inc. headquartered?
- Relmada Therapeutics, Inc. is headquartered in United States of America and employs approximately 20 people. It has been publicly traded since 2014.